EP Wealth Advisors LLC Sells 2,116 Shares of Cencora, Inc. (NYSE:COR)

EP Wealth Advisors LLC cut its holdings in shares of Cencora, Inc. (NYSE:COR) by 40.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,163 shares of the company’s stock after selling 2,116 shares during the period. EP Wealth Advisors LLC’s holdings in Cencora were worth $711,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD boosted its holdings in Cencora by 0.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 8,859,452 shares of the company’s stock valued at $1,990,542,000 after acquiring an additional 78,066 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of Cencora by 62.3% during the 4th quarter. Bank of America Corp DE now owns 5,193,807 shares of the company’s stock valued at $1,166,944,000 after purchasing an additional 1,994,256 shares in the last quarter. Boston Partners increased its position in shares of Cencora by 2.6% during the fourth quarter. Boston Partners now owns 5,007,100 shares of the company’s stock valued at $1,128,058,000 after buying an additional 125,611 shares during the period. Geode Capital Management LLC raised its stake in Cencora by 3.1% in the fourth quarter. Geode Capital Management LLC now owns 4,326,064 shares of the company’s stock worth $969,471,000 after buying an additional 130,213 shares in the last quarter. Finally, Invesco Ltd. lifted its holdings in Cencora by 20.4% in the fourth quarter. Invesco Ltd. now owns 3,243,531 shares of the company’s stock worth $728,757,000 after buying an additional 550,246 shares during the period. 97.52% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have weighed in on COR shares. Morgan Stanley set a $288.00 target price on Cencora in a report on Tuesday, April 15th. Citigroup increased their price objective on Cencora from $330.00 to $355.00 and gave the stock a “buy” rating in a report on Thursday. Robert W. Baird boosted their target price on shares of Cencora from $314.00 to $350.00 and gave the company an “outperform” rating in a report on Thursday. Wells Fargo & Company increased their price target on shares of Cencora from $251.00 to $274.00 and gave the stock an “equal weight” rating in a research note on Friday, March 14th. Finally, StockNews.com raised shares of Cencora from a “hold” rating to a “buy” rating in a research report on Wednesday, March 12th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, Cencora has a consensus rating of “Moderate Buy” and an average price target of $301.18.

Cencora Trading Down 0.2 %

Shares of NYSE COR opened at $283.12 on Friday. The firm’s 50 day moving average price is $276.48 and its 200-day moving average price is $253.44. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $309.35. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The company has a market cap of $54.90 billion, a PE ratio of 40.27, a P/E/G ratio of 1.31 and a beta of 0.60.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.07 by $0.35. The business had revenue of $75.50 billion for the quarter, compared to analysts’ expectations of $75.41 billion. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm posted $3.80 EPS. On average, equities research analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 2nd. Shareholders of record on Friday, May 16th will be given a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.78%. The ex-dividend date of this dividend is Friday, May 16th. Cencora’s dividend payout ratio (DPR) is 25.52%.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Silvana Battaglia sold 5,000 shares of the business’s stock in a transaction on Friday, February 21st. The shares were sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the sale, the executive vice president now directly owns 15,374 shares in the company, valued at approximately $3,724,197.76. The trade was a 24.54 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Robert P. Mauch sold 4,969 shares of the firm’s stock in a transaction on Monday, April 21st. The stock was sold at an average price of $289.33, for a total value of $1,437,680.77. Following the completion of the transaction, the chief executive officer now owns 47,582 shares in the company, valued at approximately $13,766,900.06. This trade represents a 9.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 50,223 shares of company stock worth $13,580,967. Company insiders own 10.80% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.